メチシリン耐性黄色ブドウ球菌(MRSA)市場:ヨーロッパ主要国の治療薬市場

◆英語タイトル:Methicillin-Resistant Staphylococcus aureus (MRSA) - 5EU Drug Forecast and Market Analysis to 2024
◆商品コード:GDHC287CFR
◆発行会社(調査会社):GlobalData
◆発行日:2015年12月16日
◆ページ数:328
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:ヨーロッパ
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD6,995 ⇒換算¥797,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD13,990 ⇒換算¥1,594,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD20,985 ⇒換算¥2,392,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Methicillin-Resistant Staphylococcus aureus (MRSA) – 5EU Drug Forecast and Market Analysis to 2024
Summary

With the discovery of penicillin, the first naturally-occurring antibiotic, in 1928, and its mass production in the early 1940s, infections with Staphylococcus aureus were mostly treatable, without any major complications. However, clinicians soon observed the emergence of penicillin-resistant strains of S. aureus, which was largely driven by bacterial expression of beta-lactamases. Methicillin, a novel penicillin analogue that was resistant to beta-lactamases, was introduced in 1959, and was initially effective against penicillin-resistant S. aureus strains. However, this success was short-lived, as the first methicillin-resistant S. aureus (MRSA) strain had been identified in the lab by 1961, and cases of MRSA were first observed in the clinic in 1968. Initially, MRSA strains only occurred in small and local outbreaks across the US and Europe, but they can now be found around the world.

For the purposes of this report, GlobalData defines the 5EU MRSA market as encompassing the sales of antimicrobial agents prescribed for the treatment of hospitalized MRSA skin infections, pneumonia, and bacteremia in France, Germany, Italy, Spain, and the UK. Importantly, revenues generated by these products outside of the aforementioned countries, patient populations, and clinical scenarios are beyond the scope of this analysis.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

- Overview of MRSA including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU MRSA market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MRSA.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in 5EU.

【レポートの目次】

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology
3.1.1 MRSA Strains
3.1.2 VISA Strains
3.1.3 VRSA Strains
3.2 Pathophysiology
3.2.1 Infection Sites
3.2.2 Expression of Virulence Factors
3.2.3 Mechanisms of Antibiotic Resistance
3.2.4 Biofilm Formation
3.3 Symptoms
3.4 Prognosis
3.4.1 Skin and Soft Tissue Infections
3.4.2 Pneumonia
3.4.3 Bacteremia
3.4.4 Chronic MRSA Infection
4 Disease Management
4.1 Diagnosis and Treatment Overview
4.1.1 Diagnosis
4.1.2 Treatment Guidelines
4.1.3 Clinical Practice
4.2 5EU
4.2.1 Forecast
4.2.2 Key Events
4.2.3 Drivers and Barriers
5 Competitive Assessment
5.1 Overview
5.2 Product Profiles – Glycopeptides and Lipoglycopeptides
5.2.1 Vancomycin
5.2.2 Dalvance (dalbavancin)
5.2.3 Orbactiv (oritavancin)
5.2.4 Vibativ (telavancin)
5.2.5 Targocid (teicoplanin)
5.3 Product Profiles – Lipopeptides
5.3.1 Cubicin (daptomycin)
5.4 Product Profiles – Oxazolidinones
5.4.1 Zyvox (linezolid)
5.4.2 Sivextro (tedizolid phosphate)
5.5 Product Profiles – Cephalosporins
5.5.1 Teflaro (ceftaroline fosamil)
5.5.2 Zevtera (ceftobiprole medocaril)
5.6 Product Profiles – Glycylcyclines
5.6.1 Tygacil (tigecycline)
5.7 Other Antimicrobial Agents
6 Unmet Need and Opportunity
6.1 Overview
6.2 Drugs with Demonstrated Efficacy in Difficult-to-Treat Patient Populations
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Expand Breadth of Clinical Data Outside of Skin Infections
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Physician Education
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Antibiotics with More Convenient Formulations and Dosing Schedules
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 Innovative Approaches to Clinical Trial Design
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
6.7 Drugs with Novel Mechanisms of Action
6.7.1 Unmet Need
6.7.2 Gap Analysis
6.7.3 Opportunity
6.8 More Affordable Therapies
6.8.1 Unmet Need
6.8.2 Gap Analysis
6.8.3 Opportunity
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Late-Stage Clinical Development
7.2.1 Delafloxacin (RX-3341)
7.2.2 Solithromycin (CEM-101)
7.2.3 Omadacycline (PTK-0796)
7.2.4 KRP-AM1977X
7.2.5 Taksta (fusidic acid, oral tablets)
7.2.6 Lefamulin (BC-3781)
7.2.7 Debio1450 (Debio1452 prodrug)
7.2.8 Brilacidin
7.3 Other Promising Products in Clinical Development
8 Market Outlook
8.1 5EU
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Hospitalized MRSA Patients
9.4.2 Percentage of Drug-Treated MRSA Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch, Label Expansion, and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research – KOLs Interviewed for This Report
9.6 Primary Research – Prescriber Survey
9.7 About the Authors
9.7.1 Author and Therapy Area Director
9.7.2 Author
9.7.3 Epidemiologist
9.7.4 Global Director of Therapy Analysis and Epidemiology
9.7.5 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

1.1 List of Tables
Table 1: Symptoms of MRSA-Associated Infections
Table 2: National and International Treatment Guidelines for MRSA Infections
Table 3: Sales Forecasts ($m) for MRSA in the 5EU, 2014-2024
Table 4: Key Events Impacting Sales for MRSA in the 5EU, 2014-2024
Table 5: MRSA Therapeutics Market - Drivers and Barriers in the 5EU, 2014-2024
Table 6: National Healthcare Authorities and Government Drug Pricing Authorities in the 5EU Nations
Table 7: Leading Branded Treatments for MRSA, 2015
Table 8: Product Profile - Vancomycin
Table 9: Vancomycin SWOT Analysis, 2015
Table 10: Global Sales Forecasts ($m) for Vancomycin, 2014-2024
Table 11: Product Profile - Dalvance
Table 12: Efficacy of Dalvance - Primary and Secondary Endpoints, DISCOVER 1 and DISCOVER 2
Table 13: Safety of Dalvance - Frequency of AEs, DISCOVER 1 and DISCOVER 2
Table 14: Dalvance SWOT Analysis, 2015
Table 15: Global Sales Forecasts ($m) for Dalvance, 2014-2024
Table 16: Product Profile - Orbactiv
Table 17: Efficacy of Orbactiv - Primary and Secondary Endpoints, SOLO I and SOLO II
Table 18: Safety of Orbactiv - Frequency of AEs, SOLO I and SOLO II
Table 19: Orbactiv SWOT Analysis, 2015
Table 20: Global Sales Forecasts ($m) for Orbactiv, 2014-2024
Table 21: Product Profile - Vibativ
Table 22: Efficacy of Vibativ - Pooled Primary and Secondary Endpoints, ATLAS 1 and ATLAS 2
Table 23: Safety of Vibativ - Frequency of AEs, ATLAS and ATTAIN Phase III Programs
Table 24: Vibativ SWOT Analysis, 2015
Table 25: Global Sales Forecasts ($m) for Vibativ, 2014-2024
Table 26: Product Profile - Targocid
Table 27: Targocid SWOT Analysis, 2015
Table 28: Global Sales Forecasts ($m) for Targocid, 2014-2024
Table 29: Product Profile - Cubicin
Table 30: Efficacy of Cubicin - Pooled Clinical Success Rates by Causative Pathogen, cSSSI Trials
Table 31: Safety of Cubicin - Frequency of AEs and SAEs
Table 32: Cubicin SWOT Analysis, 2015
Table 33: Global Sales Forecasts ($m) for Cubicin, 2014-2024
Table 34: Product Profile - Zyvox
Table 35: Efficacy of Zyvox - Primary and Secondary Endpoints, cSSSI Study in Adults
Table 36: Safety of Zyvox - Frequency of Treatment-Emergent AEs
Table 37: Zyvox SWOT Analysis, 2015
Table 38: Global Sales Forecasts ($m) for Zyvox, 2014-2024
Table 39: Product Profile - Sivextro
Table 40: Efficacy of Sivextro - Primary and Secondary Endpoints, ESTABLISH Phase III Program
Table 41: Safety of Sivextro - Frequency of Treatment-Emergent AEs, ESTABLISH-1 and ESTABLISH-2
Table 42: Sivextro SWOT Analysis, 2015
Table 43: Global Sales Forecasts ($m) for Sivextro, 2014-2024
Table 44: Product Profile - Teflaro
Table 45: Efficacy of Teflaro - Pooled Primary and Secondary Endpoints, FOCUS 1 and FOCUS 2
Table 46: Safety of Teflaro - Frequency of AEs, FOCUS and CANVAS Phase III Programs
Table 47: Teflaro SWOT Analysis, 2015
Table 48: Global Sales Forecasts ($m) for Teflaro, 2014-2024
Table 49: Product Profile - Zevtera
Table 50: Efficacy of Zevtera - Primary and Endpoints, HABP and CABP Phase III Studies
Table 51: Safety of Zevtera - Frequency of AEs, HABP and CABP Phase III Studies
Table 52: Zevtera SWOT Analysis, 2015
Table 53: Global Sales Forecasts ($m) for Zevtera, 2014-2024
Table 54: Product Profile - Tygacil
Table 55: Tygacil SWOT Analysis, 2015
Table 56: Global Sales Forecasts ($m) for Tygacil, 2014-2024
Table 57: Summary of Other Antimicrobial Agents Used for S. aureus and MRSA, 2015
Table 58: Unmet Need and Opportunity in MRSA, 2015
Table 59: Key Late-Stage Pipeline Agents for MRSA, 2015
Table 60: Product Profile - Delafloxacin
Table 61: Delafloxacin SWOT Analysis, 2015
Table 62: Global Sales Forecasts ($m) for Delafloxacin, 2014-2024
Table 63: Product Profile - Solithromycin
Table 64: Solithromycin SWOT Analysis, 2015
Table 65: Global Sales Forecasts ($m) for Solithromycin, 2014-2024
Table 66: Product Profile - Omadacycline
Table 67: Omadacycline SWOT Analysis, 2015
Table 68: Global Sales Forecasts ($m) for Omadacycline, 2014-2024
Table 69: Product Profile - KRP-AM1977X
Table 70: KRP-AM1977X SWOT Analysis, 2015
Table 71: Global Sales Forecasts ($m) for KRP-AM1977X, 2014-2024
Table 72: Product Profile - Taksta
Table 73: Taksta SWOT Analysis, 2015
Table 74: Global Sales Forecasts ($m) for Taksta, 2014-2024
Table 75: Product Profile - Lefamulin
Table 76: Lefamulin SWOT Analysis, 2015
Table 77: Global Sales Forecasts ($m) for Lefamulin, 2014-2024
Table 78: Product Profile - Debio1450
Table 79: Debio1450 SWOT Analysis, 2015
Table 80: Global Sales Forecasts ($m) for Debio1450, 2014-2024
Table 81: Product Profile - Brilacidin
Table 82: Brilacidin SWOT Analysis, 2015
Table 83: Global Sales Forecasts ($m) for Brilacidin, 2014-2024
Table 84: Other Promising Pipeline Products for MRSA, 2015
Table 85: Sales Forecasts ($m) for MRSA in the 5EU, 2014-2024
Table 86: Key Events Impacting Sales for MRSA in the 5EU, 2014-2024
Table 87: MRSA Therapeutics Market - Drivers and Barriers in the 5EU, 2014-2024
Table 88: National Healthcare Authorities and Government Drug Pricing Authorities in the 5EU Nations
Table 89: Key Historical and Projected Launch Dates for MRSA Across the 7MM
Table 90: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
Table 91: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
Table 92: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: The MRSA SCCmec Gene Cluster
Figure 2: Sites of S. aureus Infection
Figure 3: Cartoon Depicting the Key Mechanisms of Antibiotic Resistance Observed in S. aureus
Figure 4: Sales for MRSA Therapeutics by Drug Class in the 5EU, 2014 and 2024
Figure 5: Sales for MRSA Therapeutics by Country in the 5EU, 2014-2024
Figure 6: MRSA Therapeutics - Phase III/Phase II Pipeline, 2015
Figure 7: Competitive Assessment of the Recently Approved and Late-Stage Pipeline Agents in MRSA, 2014-2024
Figure 8: Sales for MRSA Therapeutics by Drug Class in the 5EU, 2014 and 2024
Figure 9: Sales for MRSA Therapeutics by Country in the 5EU, 2014-2024

★調査レポート[メチシリン耐性黄色ブドウ球菌(MRSA)市場:ヨーロッパ主要国の治療薬市場]販売に関する免責事項
★調査レポート[メチシリン耐性黄色ブドウ球菌(MRSA)市場:ヨーロッパ主要国の治療薬市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆